Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Dement Geriatr Cogn Dis Extra ; 2(1): 343-52, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22962558

ABSTRACT

BACKGROUND/AIMS: The role of cognitive reserve in Parkinson's disease (PD)-mild cognitive impairment (MCI) is incompletely understood. METHODS: The relationships between PD-MCI, years of education, and estimated premorbid IQ were examined in 119 consecutive non-demented PD patients using logistic regression models. RESULTS: Higher education and IQ were associated with reduced odds of PD-MCI in univariate analysis. In multivariable analysis, a higher IQ was associated with a significantly decreased odds of PD-MCI, but education was not. CONCLUSION: The association of higher IQ and decreased odds of PD-MCI supports a role for cognitive reserve in PD, but further studies are needed to clarify the interaction of IQ and education and the impact of other contributors such as employment and hobbies.

2.
Mov Disord ; 25(16): 2863-6, 2010 Dec 15.
Article in English | MEDLINE | ID: mdl-20818667

ABSTRACT

Recent data suggests that isradipine, a dihydropyridine calcium channel blocker, is neuroprotective in preclinical models of parkinsonism. Isradipine has not been systematically studied in patients with Parkinson's disease (PD). The aim of this study was to evaluate safety and tolerability of isradipine controlled release (CR) in patients with early PD. Qualified subjects (n = 31) received isradipine CR, titrated from 5 to 20 mg daily dose over 8 weeks as tolerated. Eighty-one percent of subjects completed the study. Tolerability of isradipine CR was dose dependent: 94% for 5 mg dose; 87% for 10 mg; 68% for 15 mg; and 52% for 20 mg. Isradipine had no significant effect on blood pressure or PD motor disability. The two most common reasons for dose reduction were leg edema (7) and dizziness (3). There was no difference in isradipine tolerability between subjects with and without dopaminergic treatment, or with and without hypertension.


Subject(s)
Calcium Channel Blockers/administration & dosage , Calcium Channel Blockers/adverse effects , Isradipine/administration & dosage , Isradipine/adverse effects , Parkinson Disease/drug therapy , Adult , Aged , Calcium Channel Blockers/therapeutic use , Humans , Isradipine/therapeutic use , Middle Aged , Pilot Projects , Treatment Outcome
4.
J Neurol Neurosurg Psychiatry ; 78(2): 147-51, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17012337

ABSTRACT

BACKGROUND: A wide variety of movement disorders may occur as a consequence of the administration of antiepileptic drugs (AEDs). Although it has been suggested that the risk of parkinsonism is 10-fold higher in those taking valproate as compared with other AEDs, there have been no large, systematic trials assessing this. AIM: To establish more precisely the prevalence of and risk factors for developing parkinsonism associated with valproate use,and to assess the occurrence of movement disorders with the newer AEDs. METHODS: Patients with epilepsy were recruited from the Toronto Western Hospital Epilepsy Clinic (University of Toronto, Toronto, Ontario, Canada). Each patient was examined by a movement disorder specialist who was blinded to the treatment status of the patient. RESULTS: 201 patients were included. Postural tremor was the most common movement disorder (45%), followed by parkinsonism (4.5%). The odds of having parkinsonism were 5 times higher with valproate than with other AEDs. No single factor predicted the presence of parkinsonism; however, many (5/9) of the patients concurrently used other drugs or had comorbidities that could have caused or exacerbated parkinsonism. None of the newer AEDs were clearly associated with the presence of movement disorders; however, the numbers were too small to make a formal analysis. CONCLUSION: Although the risk of parkinsonism with valproate is higher than with other AEDs, it is lower than originally reported. The cases available were not enough to accurately comment on the prevalence of movement disorders with the newer AEDs.


Subject(s)
Anticonvulsants/adverse effects , Parkinsonian Disorders/chemically induced , Valproic Acid/adverse effects , Adult , Aged , Anticonvulsants/therapeutic use , Cross-Sectional Studies , Epilepsy/drug therapy , Female , Humans , Male , Middle Aged , Risk Factors , Valproic Acid/therapeutic use
6.
Neurology ; 66(12): 1941-3, 2006 Jun 27.
Article in English | MEDLINE | ID: mdl-16801668

ABSTRACT

Elevated homocysteine is associated with increased risk of heart disease, stroke, and dementia. Therapy of Parkinson disease (PD) with levodopa elevates homocysteine. The authors conducted a 6-week, multicenter, randomized, double-blind, placebo-controlled trial to test whether folate 1 mg/vitamin B(12) 500 microg or entacapone reduced serum homocysteine in 35 levodopa-treated PD patients. Levodopa initiation caused a small elevation in homocysteine. Vitamin therapy, but not entacapone, resulted in a decrease in homocysteine compared to placebo.


Subject(s)
Catechols/therapeutic use , Folic Acid/administration & dosage , Hyperhomocysteinemia/chemically induced , Hyperhomocysteinemia/prevention & control , Levodopa/adverse effects , Vitamin B 12/administration & dosage , Aged , Antiparkinson Agents/therapeutic use , Canada , Double-Blind Method , Drug Combinations , Female , Homocysteine/blood , Humans , Hyperhomocysteinemia/blood , Levodopa/therapeutic use , Male , Middle Aged , Nitriles , Parkinson Disease/blood , Parkinson Disease/complications , Parkinson Disease/drug therapy , Placebo Effect , Treatment Outcome , United States , Vitamins/therapeutic use
7.
Brain ; 129(Pt 4): 832-40, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16317025

ABSTRACT

Essential palatal tremor (EPT) is an uncommon disorder, distinct from symptomatic palatal tremor (SPT), but characterized by superficially similar rhythmic movements of the soft palate. While the pathophysiology of SPT has been relatively well defined, this is not the case in EPT. Based on an analysis of 103 published cases, we reviewed EPT in the context of other movement disorders with similar features and outline possible pathophysiological mechanisms. Phenomenologically it remains best classified as a tremor. Four major causes, including a central generator, peripheral/mechanical, voluntary/special skill and psychogenic, appear to account for the majority of cases of EPT, although there is considerable overlap in the pathogenic mechanisms underlying these categories. Among the cases reviewed, a large proportion fit into the latter two categories, although there are others where multiple mechanisms are likely at play. Based on our reappraisal, we suggest a change in designation to 'isolated palatal tremor', with primary and secondary subtypes. This retains the distinction from SPT and emphasizes the non-uniform, heterogeneous nature of the disorder.


Subject(s)
Essential Tremor/classification , Mouth Diseases/classification , Adolescent , Adult , Child , Essential Tremor/etiology , Essential Tremor/physiopathology , Essential Tremor/psychology , Humans , Male , Mouth Diseases/etiology , Mouth Diseases/physiopathology , Mouth Diseases/psychology , Palatal Muscles/physiopathology , Palate, Soft/physiopathology , Psychophysiologic Disorders/etiology , Terminology as Topic
9.
S Afr Med J ; 51(11): 353-5, 1977 Mar 12.
Article in English | MEDLINE | ID: mdl-140466

ABSTRACT

A child with Down's syndrome, hydrocephalus and porencephaly is described, and treatment by compressive head binding is discussed. Although binding did not stop enlargement of the head it did achieve a reduction in the rate of enlargement.


Subject(s)
Bandages , Down Syndrome/complications , Hydrocephalus/therapy , Female , Humans , Hydrocephalus/complications , Infant , Infant, Newborn
SELECTION OF CITATIONS
SEARCH DETAIL
...